Publications
Featured Publications
Interleukin-18 Engineered For Resistance to IL-18 Binding Protein (IL-18BP) and Half-Life Extension to Enhance Its Therapeutic Potential
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Generation of tumor targeted self-assembling split IL-12p35 and IL-12p40 subunits for the treatment of cancer
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
All Publications
Using Low Dose and Intermediate-affinity IL-2 receptor agonist (Nemvaleukin alfa) with XRT to address PD1 Resistance
American Society for Therapeutic Radiology and Oncology ( ASTRO) Annual Meeting
October 2022
ARTISTRY-7: Phase 3, Multicenter Study of Nemvaleukin Alfa Plus Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa, an Investigational Cancer Immunotherapy
Population Approach Group Europe (PAGE) Meeting
June 2022
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
ARTISTRY-3: Effect of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on the Tumor Microenvironment in Patients With Advanced Solid Tumors
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
Nemvaleukin Alfa Combination Therapy for Gastrointestinal (GI) Cancers: Preclinical Evidence and Clinical Data From the ARTISTRY-1 Trial
Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI)
Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa, an Investigational Cancer Immunotherapy
Quantitative Systems Pharmacology Conference
April 2022
ARTISTRY-7: a Phase 3, Multicenter Study of Nemvaleukin Alfa, a Novel Engineered Cytokine, in Combination With Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Society of Gynecologic Oncology Annual Meeting on Women's Cancer
March 2022
Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from ARTISTRY-1
Society of Gynecologic Oncology Annual Meeting on Women's Cancer
March 2022
Nemvaleukin Alfa in Patients With Advanced Renal Cell Carcinoma: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
February 2022
Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1
Melanoma Bridge
December 2021